Published in Proc Natl Acad Sci U S A on December 01, 1977
Cladribine Tablets After Treatment With Natalizumab (CLADRINA) | NCT04178005
Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A (1978) 2.78
Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest (1985) 1.98
Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A (1978) 1.93
Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A (1979) 1.72
How I treat ADA deficiency. Blood (2009) 1.70
Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J Exp Med (1987) 1.65
Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. J Clin Invest (1978) 1.61
Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease. Proc Natl Acad Sci U S A (1979) 1.57
Erythrocyte adenosine deaminase deficiency without immunodeficiency. Evidence for an unstable mutant enzyme. J Clin Invest (1979) 1.50
Remote mutations and active site dynamics correlate with catalytic properties of purine nucleoside phosphorylase. Biophys J (2008) 1.46
Intron requirement for expression of the human purine nucleoside phosphorylase gene. Nucleic Acids Res (1992) 1.42
Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proc Natl Acad Sci U S A (1979) 1.41
The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. Biochem J (1983) 1.32
Role of adenosine deaminase, ecto-(5'-nucleotidase) and ecto-(non-specific phosphatase) in cyanide-induced adenosine monophosphate catabolism in rat polymorphonuclear leucocytes. Biochem J (1980) 1.32
S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin. Proc Natl Acad Sci U S A (1979) 1.29
Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase. Proc Natl Acad Sci U S A (1979) 1.28
Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterization. Nucleic Acids Res (1984) 1.26
Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A (1980) 1.26
Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A (2009) 1.23
Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Proc Natl Acad Sci U S A (1996) 1.20
Deoxyribonucleotide pools, base pairing, and sequence configuration affecting bromodeoxyuridine- and 2-aminopurine-induced mutagenesis. Proc Natl Acad Sci U S A (1980) 1.19
Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc Natl Acad Sci U S A (1982) 1.16
Depletion of suppressor T cells by 2'-deoxyguanosine abrogates tolerance in mice fed ovalbumin and permits the induction of intestinal delayed-type hypersensitivity. Immunology (1986) 1.14
Purine excretion by mouse peritoneal macrophages lacking adenosine deaminase activity. Proc Natl Acad Sci U S A (1979) 1.11
Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci U S A (1991) 1.09
Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation. Proc Natl Acad Sci U S A (1980) 1.09
Nucleoside exchange catalysed by the cytoplasmic 5'-nucleotidase. Biochem J (1982) 1.07
Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. Proc Natl Acad Sci U S A (1984) 1.06
ATP depletion as a consequence of adenosine deaminase inhibition in man. Proc Natl Acad Sci U S A (1980) 1.04
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood (2005) 1.03
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood (2010) 1.02
p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc Natl Acad Sci U S A (1995) 0.99
Isotope-dilution analysis of the effects of deoxyguanosine and deoxyadenosine on the incorporation of thymidine and deoxycytidine by hydroxyurea-treated thymus cells. Biochem J (1980) 0.98
Purine metabolism in myeloid precursor cells during maturation. Studies with the HL-60 cell line. J Clin Invest (1983) 0.96
Purinogenic immunodeficiency diseases. Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts. J Clin Invest (1979) 0.96
Compartmentation of guanine nucleotide precursors for DNA synthesis. Biochem J (1986) 0.95
Ecto-5'-nucleotidase activity in human T cell subsets. Decreased numbers of ecto-5'-nucleotidase positive cells from both OKT4+ and OKT8+ cells in patients with hypogammaglobulinemia. J Clin Invest (1983) 0.93
Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy. J Clin Invest (1981) 0.91
Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med (2000) 0.90
Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts. J Clin Invest (1984) 0.87
Development of oral cladribine for the treatment of multiple sclerosis. J Neurol (2010) 0.86
Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. J Clin Invest (1995) 0.86
Metabolic defects in immunodeficiency diseases. Clin Exp Immunol (1982) 0.85
Sequence and functional characterization of the human purine nucleoside phosphorylase promoter. Nucleic Acids Res (1991) 0.83
Adenosine-induced apoptosis in chick embryonic sympathetic neurons: a new physiological role for adenosine. J Physiol (1995) 0.83
Point mutations at the purine nucleoside phosphorylase locus impair thymocyte differentiation in the mouse. Proc Natl Acad Sci U S A (1997) 0.82
Heberden oration 1979: human aberrations of purine metabolism and their significance for rheumatology. Ann Rheum Dis (1980) 0.82
Nucleoside kinases in T and B lymphoblasts distinguished by autoradiography. Proc Natl Acad Sci U S A (1986) 0.82
Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice. PLoS One (2012) 0.81
Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther (2011) 0.81
Cladribine Analogues via O⁶-(Benzotriazolyl) Derivatives of Guanine Nucleosides. Molecules (2015) 0.81
Resistance of pokeweed mitogen-stimulated B cells to inhibition by deoxyadenosine. Clin Exp Immunol (1980) 0.81
Lymphocyte purine metabolism -- significance of 5'-nucleotidase deficiency: a review. J R Soc Med (1979) 0.81
Deoxycytidine kinase promotes the migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients. Int J Clin Exp Pathol (2013) 0.80
Phosphorylation of deoxyguanosine by B and T lymphocytes: evidence against selective trapping of deoxyguanosine by T lymphocytes in purine nucleoside phosphorylase deficiency. Clin Exp Immunol (1980) 0.80
B cells as well as T cells form deoxynucleotides from either deoxyadenosine or deoxyguanosine. Clin Exp Immunol (1984) 0.79
Managing MS in a changing treatment landscape. J Neurol (2011) 0.79
Further differentiation of murine double-positive thymocytes is inhibited in adenosine deaminase-deficient murine fetal thymic organ culture. J Immunol (2006) 0.79
Molecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiency. Am J Hum Genet (1992) 0.79
Genomic structure and chromosomal localization of the human deoxycytidine kinase gene. Proc Natl Acad Sci U S A (1993) 0.78
Deficiency of purine nucleoside phosphorylase activity in thymocytes from the immunodeficient diabetic BB rat. Clin Exp Immunol (1991) 0.77
Restoring balance to B cells in ADA deficiency. J Clin Invest (2012) 0.77
Adenosine deaminase deficiency: unanticipated benefits from the study of a rare immunodeficiency. J Immunol (2012) 0.77
Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP. Biochem J (1990) 0.75
Combined immunodeficiency and thymic abnormalities. J Clin Pathol Suppl (R Coll Pathol) (1979) 0.75
Relative sensitivity of human T cell subsets to deoxyadenosine toxicity. Clin Exp Immunol (1984) 0.75
In vitro of adenosine on lymphocytes and erythrocytes from horses with combined immunodeficiency. J Clin Invest (1979) 0.75
Adenine ribo- and deoxyribonucleotide metabolism in human erythrocytes, B- and T-lymphocyte cell lines, and monocyte-macrophages. Proc Natl Acad Sci U S A (1985) 0.75
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Drug Des Devel Ther (2010) 0.75
Potential immunological action of purine nucleoside analogues. Drugs (1994) 0.75
Infusion of Sibling Marrow in a Patient with Purine Nucleoside Phosphorylase Deficiency Leads to Split Mixed Donor Chimerism and Normal Immunity. Front Pediatr (2017) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
An extension of the 51Cr-release assay for the estimation of mouse cytotoxins. Transplantation (1968) 9.80
Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet (1972) 9.01
Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet (1975) 5.15
ION-EXCHANGE CHROMATOGRAPHY OF NUCLEOTIDES ON POLY-(ETHYLENEIMINE)-CELLULOSE THIN LAYERS. J Chromatogr (1964) 3.36
Pyrimidine starvation induced by adenosine in fibroblasts and lymphoid cells: role of adenosine deaminase. Science (1973) 2.37
Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem (1976) 2.14
Regulation of mammalian deoxyribonucleotide biosynthesis by nucleotides as activators and inhibitors. J Biol Chem (1966) 1.97
Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate. Science (1975) 1.92
Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase. N Engl J Med (1976) 1.91
Rapid determination of nucleoside kinase and nucleotidase activities with tritium-labeled substrates. Anal Biochem (1969) 1.69
Restoration of in-vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency. Lancet (1975) 1.50
Evidence for control of several different tissue-specific isozymes of adenosine deaminase by a single genetic locus. Nat New Biol (1973) 1.48
Further studies on the effect of deoxyadenosine on the accumulation of deoxyadenosine triphosphate and inhibition of deoxyribonucleic acid synthesis in Ehrlich ascites tumor cells in vitro. Biochim Biophys Acta (1962) 1.43
Purine metabolism in adenosine deaminase deficiency. Proc Natl Acad Sci U S A (1976) 1.43
Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis. J Clin Invest (1976) 1.36
Deoxycytidine kinase. I. Distribution in normal and neoplastic tissues and interrelationships of deoxycytidine and 1-beta-D-arabinofuranosylcytosine phosphorylation. Mol Pharmacol (1969) 1.35
Adenosine deaminase from human erythrocytes: purification and effects of adenosine analogs. Biochem Pharmacol (1975) 1.33
Rate-limiting steps in the interconversion of purine ribonucleotides in Ehrlich ascites tumor cells in vitro. Cancer Res (1971) 1.33
Adenosine metabolism in phytohemagglutinin-stimulated human lymphocytes. J Clin Invest (1976) 1.29
Alternative pathways of deoxyadenosine and adenosine metabolism. J Biol Chem (1973) 1.27
Expression of purine overproduction in a series of 8-azaguanine-resistant diploid human lymphoblast lines. Proc Natl Acad Sci U S A (1974) 1.25
Deoxycytidine kinase. II. Purification and general properties of the calf thymus enzyme. J Biol Chem (1970) 1.24
Purification and properties of adenosine kinase from human tumor cells of type H. Ep. No. 2. J Biol Chem (1967) 1.22
Purine nucleoside phosphorylase from human erythroyctes. II. Kinetic analysis and substrate-binding studies. J Biol Chem (1968) 1.22
Adenosine deaminase activity in thymus and other human tissues. Clin Exp Immunol (1976) 1.19
4th FEBS Meeting's Plenary Lecture. The biosynthesis of deoxyribonucleotides. Eur J Biochem (1968) 1.19
Transport of nucleosides. Ann N Y Acad Sci (1975) 1.17
Purine dysfunction in cells from patients with adenosine deaminase deficiency. Pediatr Res (1976) 1.06
Mammalian deoxynucleoside kinases. II. Deoxyadenosine kinase: purification and properties. J Biol Chem (1971) 0.99
Regulatory mechanisms in the synthesis of deoxyribonucleic acid in vitro. Biochim Biophys Acta (1960) 0.98
Successful fetal liver transplantation in a child with severe combined immunodeficiency. Lancet (1975) 0.97
Measurement of free nucleotides in cultured human lymphoid cells using high pressure liquid chromatography. Biochem Med (1977) 0.92
Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science (1967) 7.75
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (1994) 6.06
Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol (1984) 5.51
Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted. J Virol (1992) 5.18
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 3.82
A specific enzyme defect in gout associated with overproduction of uric acid. Proc Natl Acad Sci U S A (1967) 3.29
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01
Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science (1988) 2.96
B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med (1988) 2.88
Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Intern Med (1969) 2.84
Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest (1989) 2.83
Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest (1991) 2.82
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology (2009) 2.74
Motor slowing precedes cognitive impairment in the oldest old. Neurology (1998) 2.74
THE INFLUENCE OF IODINE ON THE EXCRETION OF CREATINE IN EXOPHTHALMIC GOITER. J Clin Invest (1929) 2.73
Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A (1994) 2.58
The occurrence of new mutants in the X-linked recessive Lesch-Nyhan disease. Am J Hum Genet (1976) 2.51
Voluntary regionalization and associated trends in perinatal care: the Nova Scotia Reproductive Care Program. Am J Obstet Gynecol (1983) 2.45
Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. J Biol Chem (1988) 2.41
In vitro effects of Epstein-Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects. J Exp Med (1978) 2.34
Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J Natl Cancer Inst (2000) 2.33
Radioimmunoassay of IgG and IgM rheumatoid factors reacting with human IgG. J Immunol (1977) 2.21
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology (2006) 2.21
Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med (1996) 2.18
Increased cystine in leukocytes from individuals homozygous and heterozygous for cystinosis. Science (1967) 2.12
Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem (1968) 2.08
Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Ann Neurol (1997) 2.07
A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. Oncogene (2000) 2.07
Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies (rheumatoid factors). A structural explanation for the high frequency of IgM anti-IgG B cells. J Exp Med (1986) 2.04
Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A (1996) 2.01
Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest (1985) 1.98
Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science (1987) 1.97
A conserved human germline V kappa gene directly encodes rheumatoid factor light chains. J Exp Med (1986) 1.92
A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology (2008) 1.91
IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol (1990) 1.82
Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci U S A (2000) 1.81
Talking while walking: the effect of a dual task in aging and Alzheimer's disease. Neurology (1997) 1.81
Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci U S A (1978) 1.79
Assessing the privacy risks of data sharing in genomics. Public Health Genomics (2010) 1.78
Urine uric acid to creatinine rtio--a screening test for inherited disorders of purine metabolism. Phosphoribosyltransferase (PRT) deficiency in X-linked cerebral palsy and in a variant of gout. J Pediatr (1968) 1.76
Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. J Exp Med (1988) 1.73
Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A (1979) 1.72
Hyperuricemia and gout. Classification, complications and management. N Engl J Med (1979) 1.71
Suppression of metabolic accompaniments of phagocytosis by colchicine. Arthritis Rheum (1965) 1.70
Rheumatoid factor and immune networks. Annu Rev Immunol (1987) 1.70
Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry (2003) 1.70
In vivo and in vitro clonal deletion of double-positive thymocytes. J Exp Med (1992) 1.66
Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1989) 1.66
Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell (1989) 1.66
2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol (1992) 1.65
A common idiotope on human rheumatoid factors identified by a hybridoma antibody. Mol Immunol (1983) 1.65
Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J Exp Med (1987) 1.65
IgG rheumatoid factor in subacute bacterial endocarditis: relationship to IgM rheumatoid factor and circulating immune complexes. Clin Exp Immunol (1978) 1.62
DNA strand breaks, NAD metabolism, and programmed cell death. Exp Cell Res (1986) 1.60
Increased free-cystine content of fibroblasts cultured from patients with cystinosis. Biochem Biophys Res Commun (1967) 1.58
Induction of receptors for interleukin 2 requires T cell Ag:Ia receptor crosslinking and interleukin 1. Lymphokine Res (1984) 1.57
An enzymatic spectrophotometric method for the determination of xanthine and hypoxanthine. Clin Chem (1967) 1.57
A 16/6 idiotype-positive anti-DNA antibody is encoded by a conserved VH gene with no somatic mutation. Arthritis Rheum (1988) 1.56
Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1990) 1.55
Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-gamma. Eur J Immunol (1985) 1.55
Evidence for the presence of receptors for C3 and IgG Fc on human synovial cells. Arthritis Rheum (1980) 1.54
Transforming growth factor-beta and cellular immune responses in synovial fluids. J Immunol (1990) 1.53
Activation of resting T lymphocytes by anti-CD3 (T3) antibodies in the absence of monocytes. J Immunol (1985) 1.53
Substituted isoquinolines and quinazolines as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha. J Med Chem (1999) 1.52
Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc Natl Acad Sci U S A (1989) 1.52
Autocrine growth inhibition of a cloned line of helper T cells. Proc Natl Acad Sci U S A (1986) 1.51
Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein-Barr virus nuclear antigen. J Exp Med (1987) 1.50
Anti-hypervariable region antibody induced by a defined peptide: an approach for studying the structural correlates of idiotypes. Proc Natl Acad Sci U S A (1984) 1.50
Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology (2007) 1.48
Evidence for intergenic complementation in hybrid cells derived from two human diploid strains each carrying an X-linked mutation. Proc Natl Acad Sci U S A (1969) 1.48
Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood (2000) 1.47
Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum (2001) 1.46
Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies. J Clin Invest (1986) 1.46
Urinary xanthine stones--a rare complications of allopurinol therapy. N Engl J Med (1969) 1.45
Increased risk of familial late-onset Alzheimer's disease in women. Neurology (1996) 1.45
An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency. N Engl J Med (1968) 1.45
IgA rheumatoid factor in the sera and saliva of patients with rheumatoid arthritis and Sjögren's syndrome. Ann Rheum Dis (1979) 1.45
Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proc Natl Acad Sci U S A (1979) 1.44
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood (1983) 1.43
The Epstein-Barr virus glycoprotein gp110, a molecular link between HLA DR4, HLA DR1, and rheumatoid arthritis. Scand J Immunol (1988) 1.43
Hypoxanthine-guanine phosphoribosyltransferase deficiency: activity in normal, mutant, and heterozygote-cultured human skin fibroblasts. Proc Natl Acad Sci U S A (1970) 1.42
Inheritance of immunoglobulin M rheumatoid-factor idiotypes. J Clin Invest (1980) 1.41
Adenine and adenosine are toxic to human lymphoblast mutants defective in purine salvage enzymes. Science (1977) 1.40
Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J Immunol (1978) 1.40
Osteopathy: the 'orthodox' alternative. Occup Health (Lond) (1992) 1.40
Report may lead to population collection by the back door. BMJ (2001) 1.40
Delineation of a cross-reactive idiotype on human autoantibodies with antibody against a synthetic peptide. J Exp Med (1984) 1.40
The majority of human monoclonal IgM rheumatoid factors express a "primary structure-dependent" cross-reactive idiotype. J Immunol (1985) 1.40
Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells. J Biol Chem (1982) 1.39
Adenosine deaminase deficiency and severe combined immunodeficiency disease. Adv Enzymol Relat Areas Mol Biol (1980) 1.39
Incidence of three cross-reactive idiotypes on human rheumatoid factor paraproteins. J Immunol (1988) 1.39